Search

Your search keyword '"Samuel Z. Goldhaber"' showing total 905 results

Search Constraints

Start Over You searched for: Author "Samuel Z. Goldhaber" Remove constraint Author: "Samuel Z. Goldhaber"
905 results on '"Samuel Z. Goldhaber"'

Search Results

1. Association of body mass index with outcomes in patients with newly diagnosed atrial fibrillation: GARFIELD-AF

2. On-treatment Comparative Effectiveness of Vitamin K Antagonists and Direct Oral Anticoagulants in GARFIELD-VTE, and Focus on Cancer and Renal Disease

3. Risk of Recurrent Venous Thromboembolism in Selected Subgroups of Men: A Danish Nationwide Cohort Study

4. Patients with myeloproliferative neoplasms and COVID‐19 have increased rates of arterial thrombosis

5. Provoked versus unprovoked venous thromboembolism: Findings from GARFIELD‐VTE

6. Machine learning to predict venous thrombosis in acutely ill medical patients

7. Optimization of DOAC management services in a centralized anticoagulation clinic

8. Association Between Preexisting Versus Newly Identified Atrial Fibrillation and Outcomes of Patients With Acute Pulmonary Embolism

9. Safety, Efficacy of an Accelerated Regimen of Low-Dose Recombinant Tissue-Type Plasminogen Activator for Reperfusion Therapy of Acute Pulmonary Embolism

10. Global reporting of pulmonary embolism–related deaths in the World Health Organization mortality database: Vital registration data from 123 countries

11. Association of Socioeconomic Disadvantage With Mortality and Readmissions Among Older Adults Hospitalized for Pulmonary Embolism in the United States

12. Pregnancy-Associated Venous Thromboembolism: Insights from GARFIELD-VTE

13. Risk profiles and one-year outcomes of patients with newly diagnosed atrial fibrillation in India: Insights from the GARFIELD-AF Registry

14. Estimation of Acutely Ill Medical Patients at Venous Thromboembolism Risk Eligible for Extended Thromboprophylaxis Using APEX Criteria in US Hospitals

15. Evaluation of Antifactor-Xa Heparin Assay and Activated Partial Thromboplastin Time Values in Patients on Therapeutic Continuous Infusion Unfractionated Heparin Therapy

16. Characterization of Major and Clinically Relevant Non-Major Bleeds in the APEX Trial

17. Apixaban for Primary Prevention of Venous Thromboembolism in Patients With Multiple Myeloma Receiving Immunomodulatory Therapy

18. Management and 1‐Year Outcomes of Patients With Newly Diagnosed Atrial Fibrillation and Chronic Kidney Disease: Results From the Prospective GARFIELD‐AF Registry

20. Anticoagulation and Mortality Rates among Hospitalized Patients with Atrial Fibrillation

21. Heparin-Induced Thrombocytopenia in Healthy Individuals with Continuous Heparin Infusion

22. Association of D-dimer Levels with Clinical Event Rates and the Efficacy of Betrixaban versus Enoxaparin in the APEX Trial

23. Trends in Perioperative Venous Thromboembolism Associated with Major Noncardiac Surgery

24. Comparison of Fatal or Irreversible Events With Extended‐Duration Betrixaban Versus Standard Dose Enoxaparin in Acutely Ill Medical Patients: An APEX Trial Substudy

25. The IMPROVEDD VTE Risk Score: Incorporation of D-Dimer into the IMPROVE Score to Improve Venous Thromboembolism Risk Stratification

26. Comparing Two Medicines to Prevent Blood Clots after Treatment for Fractures – The PREVENT CLOT Study

28. Catheter-Directed Thrombolysis vs Anticoagulation in Patients With Acute Intermediate-High-risk Pulmonary Embolism: The CANARY Randomized Clinical Trial

29. Developing Validated Tools to Identify Pulmonary Embolism in Electronic Databases: Rationale and Design of the PE-EHR+ Study

30. Coronary Flow Reserve, Inflammation, and Myocardial Strain

31. 36-month clinical outcomes of patients with venous thromboembolism

33. Stroke and Myocardial Infarction in Patients with Abdominal Aortic Aneurysm and New-Onset Atrial Fibrillation

34. Direct Oral Anticoagulants vs Vitamin K Antagonists in Patients With Antiphospholipid Syndromes

35. GARFIELD-AF: risk profiles, treatment patterns and 2-year outcomes in patients with atrial fibrillation in Germany, Austria and Switzerland (DACH) compared to 32 countries in other regions worldwide

36. Anticoagulation-associated Adverse Drug Events in Hospitalized Patients Across Two Time Periods

37. Major cardiovascular events after COVID-19, event rates post-vaccination, antiviral or anti-inflammatory therapy, and temporal trends: Rationale and methodology of the CORONA-VTE-Network study

38. Temporal trends in abdominal aortic aneurysmal disease: a nationwide cohort study on cardiovascular morbidity and medical cardioprotective therapy

39. Sex Differences in PrEsentation, Risk Factors, Drug and Interventional Therapies, and OUtcomes of Elderly PatientS with Pulmonary Embolism: Rationale and design of the SERIOUS-PE study

41. Early Detection and Management of Venous Thrombosis in Skull Base Surgery: Role of Routine Doppler Ultrasound Monitoring

42. Acute Management of High-Risk and Intermediate-Risk Pulmonary Embolism in Children

43. Atorvastatin versus Placebo in ICU Patients with COVID-19: Ninety-day Results of the INSPIRATION-S Trial

44. Meningioma resection and venous thromboembolism incidence, management, and outcomes

45. Comparing Two Medicines to Prevent Blood Clots after Treatment for Fractures – The PREVENT CLOT Study

46. Influence of body mass index on clinical outcomes in venous thromboembolism: Insights from GARFIELD‐VTE

47. Investigating Lipid-Modulating Agents for Prevention or Treatment of COVID-19

48. Safety and effectiveness of dabigatran in routine clinical practice: the RE-COVERY DVT/PE study

49. Cerebral Venous Sinus Thrombosis in the U.S. Population, After Adenovirus-Based SARS-CoV-2 Vaccination, and After COVID-19

50. Direct Oral Anticoagulants vs Vitamin K Antagonists in Patients With Antiphospholipid Syndromes: Meta-Analysis of Randomized Trials

Catalog

Books, media, physical & digital resources